FDA advisory panel recommends updated COVID-19 booster vaccinations that target Omicron variant for next wave of boosters; Pfizer, Moderna report positive results from updated shots, with final decision from FDA to come later

Sample article from our Tissue & Hygiene

TOKYO , June 30, 2022 (press release) –

TOKYO, June 29 -- NHK World issued the following news:

An advisory panel of the U.S. Food and Drug Administration has recommended that coronavirus booster vaccine shots be updated to target the highly transmissible Omicron variant.

Advisers on the committee met on Tuesday and voted 19-2 that the next wave of boosters should include a component targeting Omicron.

They discussed whether vaccines currently being developed to combat the variant should be used.

The FDA noted that booster shots are needed as vaccines lose their efficacy with time. It also said it may be necessary to change the design of the vaccines so that they can better combat virus variants.

Vaccine makers Pfizer and Moderna reported the results of clinical tests on their updated versions designed against the BA.1 Omicron variant. The two companies said data showed that their booster shots significantly increased neutralizing antibodies in recipients.

Some experts said vaccines currently being used as boosters are already effective in preventing deaths and hospitalizations.

Others said vaccines should be designed to target not BA.1, but the BA.4 and BA.5 subvariants. These subvariants have been increasingly responsible for recent outbreaks.

The FDA is expected to decide what boosters to use before the next wave, which is anticipated in the fall. For any query with respect to this article or any other content requirement, please contact Editor at contentservices@htlive.com

(c) 2022 HT Digital Content Services

* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.

See our dashboard in action - schedule an demo
Dan Rivard
Dan Rivard
- VP Market Development -

We offer built-to-order tissue & hygiene coverage for our clients. Contact us for a free consultation.

About Us

We deliver market news & information relevant to your business.

We monitor all your market drivers.

We aggregate, curate, filter and map your specific needs.

We deliver the right information to the right person at the right time.

Our Contacts

1990 S Bundy Dr. Suite #380,
Los Angeles, CA 90025

+1 (310) 553 0008

About Cookies On This Site

We collect data, including through use of cookies and similar technology ("cookies") that enchance the online experience. By clicking "I agree", you agree to our cookies, agree to bound by our Terms of Use, and acknowledge our Privacy Policy. For more information on our data practices and how to exercise your privacy rights, please see our Privacy Policy.